Genetic differences between individuals that affect drug action form a challenge in drug therapy. Many drugs target G protein-coupled receptors (GPCRs), and a number of receptor variants have been noted to impact drug efficacy. This, however, has never been addressed in a systematic way, and, hence, we studied real-life genetic variation of receptor function in personalized cell lines. As a showcase we studied adenosine A2A receptor (A2AR) signaling in lymphoblastoid cell lines (LCLs) derived from a family of four from the Netherlands Twin Register (NTR), using a non-invasive label-free cellular assay. The potency of a partial agonist differed significantly for one individual. Genotype comparison revealed differences in two intron SNPs including rs2236624, which has been associated with caffeine-induced sleep disorders. While further validation is needed to confirm genotype-specific effects, this set-up clearly demonstrated that LCLs are a suitable model system to study genetic influences on A2AR response in particular and GPCR responses in general.

Copyright © 2016 Elsevier Inc. All rights reserved.

Overview publication

TitleGetting personal: Endogenous adenosine receptor signaling in lymphoblastoid cell lines.
DateSeptember 1st, 2016
Issue nameBiochemical pharmacology
Issue numberv115:114-22
DOI10.1016/j.bcp.2016.06.006
PubMed27297283
AuthorsHillger JM, Diehl C, van Spronsen E, Boomsma DI, Slagboom PE, Heitman LH & IJzerman AP
KeywordsAdenosine (PubChem CID: 60961), Adenosine A(2A) receptor, BAY60-6583 (PubChem CID: 11717831), CCPA (PubChem CID: 123807), CGS21680 (PubChem CID: 3086599), Cl-IB-MECA (PubChem CID: 3035850), G protein-coupled receptors, Istradefylline (PubChem CID: 5311037), LUF5448 (PubChem CID: 69538223), Label-free, Lymphoblastoid cell lines, NECA (PubChem CID: 448222), Precision medicine, Single Nucleotide Polymorphism, ZM241385 (PubChem CID: 176407)
Read Read publication